Teva Pharmaceutical Industries (TEVA) Non-Current Assets (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Non-Current Assets for 18 consecutive years, with $26.3 billion the latest figure, recorded in Q1 2026.

• Quarterly Non-Current Assets fell 2.07% year-over-year to $26.3 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $107.8 billion (down 4.47% YoY) and the FY2025 annual result came in at $26.8 billion, changed 0.1% from the prior year.
• Non-Current Assets retreated to $26.3 billion in Q1 2026 per TEVA's latest filing, from $26.8 billion in the prior quarter.
• Over the last five years, Non-Current Assets for TEVA reached as high as $34.6 billion in Q1 2022 and fell as low as $26.3 billion in Q1 2026.
• A 5-year average of $29.9 billion and a median of $30.5 billion in 2024 frame the typical range for Non-Current Assets.
• Annual changes were most pronounced in 2024 — Non-Current Assets retreated 13.62% — and 2025, when it climbed 0.1%.
• Year by year, Non-Current Assets stood at $32.0 billion in 2022, then retreated by 3.02% to $31.0 billion in 2023, then fell by 13.62% to $26.8 billion in 2024, then advanced by 0.1% to $26.8 billion in 2025, then slipped by 1.76% to $26.3 billion in 2026.
• According to Business Quant data, Non-Current Assets over the past three periods registered $26.3 billion, $26.8 billion, and $27.1 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.